Immunologic Research

, Volume 49, Issue 1, pp 49–55

Prevention of GVHD without losing GVL effect: windows of opportunity


DOI: 10.1007/s12026-010-8193-7

Cite this article as:
Zhang, P., Chen, B.J. & Chao, N.J. Immunol Res (2011) 49: 49. doi:10.1007/s12026-010-8193-7


Allogeneic hematopoietic cell transplantation has developed into a most successful form of immunotherapy for hematologic malignancies in the past 50 years. However, its effectiveness and wider applications have been greatly limited by the development of graft-versus-host disease (GVHD), a potentially lethal side effect associated with this procedure. Since the main effectors for both graft-versus-leukemia (GVL) effect and GVHD are T lymphocytes and these two processes share many similar pathways, it has not been easy to separate GVL from GVHD. Because the clinically used pan immunosuppressive therapy for GVHD prevention also results in decreased GVL effect, the success of allogeneic hematopoietic cell transplantation relies on a small and unpredictable therapeutic window at the present time. This review discusses how we may widen this therapeutic window so that we can reliably prevent GVHD without losing GVL effect.


Graft-versus-host disease Graft-versus-leukemia T lymphocytes Memory T cells Allogeneic hematopoietic stem cell transplantation 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of MedicineDuke University Medical CenterDurhamUSA
  2. 2.Department of Medicine and ImmunologyDuke University Medical CenterDurhamUSA

Personalised recommendations